Virasoft is a technology company.
Virasoft has raised $3.4M across 2 funding rounds.
Virasoft has raised $3.4M in total across 2 funding rounds.
Virasoft is a technology company specializing in AI-powered digital pathology solutions for cancer diagnosis, workflow optimization, and research. It develops products like Anatomic Pathology Laboratory Information Systems (APLIS), Image Management Systems (IMS), AI-based decision support algorithms, telepathology platforms, and academic training tools, serving pathology labs, research institutions, and clinicians worldwide.[1][2][4][6] Headquartered in New York with R&D in Istanbul, Turkey, Virasoft processes 400,000 cases annually across 20+ institutions, enhancing diagnostic accuracy and efficiency for hundreds of pathologists.[1][2] The company has raised $4.4M in funding, including a $2.5M Series A-II round about three years ago, and continues to expand through partnerships like those with Huawei and labs such as Istinye University and Pathoteam Diagnostic.[6][7]
Virasoft was founded in 2015 (with some sources noting 2016 or 2017 as key milestones) by two childhood friends and engineers, including figures like Firat Ozpinar and Samet, motivated by the high cancer rates in their hometowns affected by the 1986 Chernobyl disaster.[2][3][5][7] Supported initially by Turkey's Ministry of Industry TGSD, the company emerged from a drive to merge pathology with AI and digital tools for better cancer diagnostics.[5][7] Early traction came from pathology labs adopting solutions in 2019, followed by global expansion: establishing New York headquarters in 2022 while retaining Istanbul R&D, and building an advisory board of US- and Turkey-based experts in computer science and anatomic pathology.[1][2] Pivotal moments include presentations at major congresses like USCAP, ECP, and ECDP, and implementations boosting lab workflows.[6]
Virasoft rides the digital pathology wave, fueled by AI advancements in image recognition and healthcare automation amid rising global cancer burdens. Its timing aligns with post-pandemic telehealth acceleration and regulatory shifts favoring AI diagnostics, positioning it against giants like Microsoft and IBM in a market demanding faster, precise pathology amid pathologist shortages.[1][6] Favorable forces include exploding demand for quantitative analysis (e.g., in breast cancer) and workflow digitization, as seen in Huawei showcases and European congress integrations.[6][7] By curating real clinical data for deep-learning models and enabling telepathology, Virasoft influences the ecosystem, democratizing advanced tools for emerging markets like Turkey while scaling to US labs, fostering broader adoption of AI in oncology.[2][5]
Virasoft's momentum—evident in 2025 congress posters, lab rollouts, and AI expansions—signals acceleration toward deeper global penetration, potentially via more Series funding or acquisitions. Trends like multimodal AI (combining imaging, NLP, and genomics) and regulatory approvals will shape its path, amplifying impact in underserved regions. Its influence may evolve from niche innovator to ecosystem leader, powering precision oncology as digital pathology matures, fulfilling the founders' mission to combat cancer at scale.[2][6] This resilience-driven journey underscores how personal purpose fuels tech breakthroughs in healthcare.
Virasoft has raised $3.4M in total across 2 funding rounds.
Virasoft's investors include Diffusion Capital Partners.
Virasoft has raised $3.4M across 2 funding rounds. Most recently, it raised $3.0M Seed in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $3.0M Seed | Diffusion Capital Partners | |
| Aug 1, 2017 | $420K Seed | Diffusion Capital Partners |